Nemaura Medical Inc. Stock News

The Business Research Company’s Diabetes Care Devices Global Market Report 2020-30: Covid-19 Impact On Diabetes Care Devices Market

Wall Street brokerages expect that DexCom, Inc. (NASDAQ:DXCM) will post earnings of $0.28 per share for the current fiscal quarter, Zacks Investment Research reports. Ten analysts have provided estima

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable dia

Nemaura Medical Inc (OTCMKTS:NMRD)’s stock price rose 3% during trading on Monday . The company traded as high as $16.50 and last traded at $15.27, approximately 43,565 shares changed hands during m

DexCom (NASDAQ:DXCM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Monday, Zacks.com reports. They currently have a $430.00

Nemaura Medical, Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable dia

Strong COVID-19 programs, great growth prospects, attractive dividends. These stocks check off all the boxes.

Which of these two diabetes partners is more likely to be the bigger winner over the long run?

DexCom, Inc. (NASDAQ:DXCM) Director Nicholas Augustinos sold 1,875 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $366.65, for a

As the prevalence of diabetes has grown, these companies are looking for solutions.

DexCom, Inc. (NASDAQ:DXCM) insider Andrew K. Balo sold 6,522 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $366.47, for a total tr

DexCom (NASDAQ:DXCM) had its price target raised by equities researchers at Bank of America from $375.00 to $500.00 in a report issued on Wednesday, BenzingaRatingsTable reports. The brokerage present